Global burden for blindness and vision loss among women of childbearing age and perimenopause: age-period-cohort analysis 2021.

Yixian Liu, Yi Zeng, Rong Rong, Xiaobo Xia

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yixian Liu *Eye Center of Xiangya Hospital, Central South University, Changsha, 410008, Hunan, P.R. China.

Yi Zeng *Eye Center of Xiangya Hospital, Central South University, Changsha, 410008, Hunan, P.R. China.

Rong RongEye Center of Xiangya Hospital, Central South University, Changsha, 410008, Hunan, P.R. China. rrong99@csu.edu.cn.

Xiaobo XiaEye Center of Xiangya Hospital, Central South University, Changsha, 410008, Hunan, P.R. China. xbxia21@csu.edu.cn.

Funding

China Postdoctoral Science Foundation 2023M743952National Natural Science Foundation of China 82401261National Postdoctoral Program for Innovative Talents BX20230434Scientific Research Program of FuRong Laboratory 2024PT5107the Youth Science Foundation of Xiangya Hospital 2023Q12

6 · The paper itself

Abstract

Blinding eye disease is a major threat to global public health, and adult women represent a significant portion of this population. This study aimed to characterize the prevalence and trends of blinding eye diseases and vision loss in women of childbearing age (WCBA) and Perimenopause (PMW), to provide important information for the future development of more effective preventive and interventional measures for eye diseases in women. In 2021, the global prevalence of BVL disease in WCBA and PMW was 333 million. Forty countries and regions have more than one million people with BVL disease in both WCBA and PMW. India, China, Brazil, and Indonesia are the top 4 countries with more than ten million people. The BAPC model predicts that there will be 800 million cases of BVL in WCBA and PMW worldwide by 2050. This study comprehensively analyzed global trends in the burden of BVL disease in WCBA and PMW between 1992 and 2021. The results show a significant increase in the prevalence and burden of BVL, particularly concentrated in older female populations.

Indexed as

BlindnessGlobal Burden of DiseasePerimenopauseAdultCohort StudiesFemaleGlobal HealthHumansMiddle AgedPrevalenceYoung AdultAge-period-cohort modelsBlindness and vision lossGlobal burden of disease studyWomen of child-bearing age and Perimenopause

Identifiers

PMID41741584

DOI10.1038/s41598-026-41588-y

PMCPMC13044264

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.